title: Minimization of immunosuppressive therapy after islet transplantation: combined action of heme oxygenase-1 and PEGylation to islet.
abstract: We previously established a type of PEGylated islets to attenuate cellular immune reactions by immobilizing polyethylene glycol (PEG) molecules on islet surfaces, thereby synergistically reducing the dose of immunosuppressant cyclosporine A (CsA; 3 mg/kg/day) to protect transplanted islets. However, higher doses of immunosuppressants should be administered after islet transplantation due to nonspecific inflammation. This study documents that PEGylated islets can be cooperatively protected by the systemic overexpression of heme oxygenase-1 (HO-1), which has a potent cytoprotective function in preventing nonspecific inflammation during an early stage following islet transplantation. Under this scheme, the viability of PEGylated islets was improved; that is, PEG molecules could block cellular immunity and HO-1 could exert its cytoprotective property against inflammation. Interestingly, when employed with a low dose of CsA (1 mg/kg/day), a cooperative action of PEG molecules and HO-1 in immune reactions could result in the complete survival of transplanted islets for 100 days without islet function impairment. However, unmodified islets (control) were completely rejected within 2 weeks despite cotreatment with HO-1 expression and CsA. These results demonstrated that the combinatorial protocol of initial induction of HO-1 expression, followed by the daily administration of a low dose CsA after transplantation of PEGylated islets can be employed as a successful cell therapy in clinical islet transplantation.
authors.affiliation: College of Pharmacy, Seoul National University, South Korea.
authors.forename: D Y
authors.initials: DY
authors.lastname: Lee
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.forename: J H
authors.initials: JH
authors.lastname: Nam
authors.forename: Y
authors.initials: Y
authors.lastname: Byun
mesh_terms: D000818:Animals; D003035:Cobalt / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology*; D006085:Graft Survival / Q000187:drug effects; D051547:Heme Oxygenase-1 / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007515:Islets of Langerhans / Q000187:drug effects / Q000201:enzymology* / Q000276:immunology* / Q000378:metabolism; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D008297:Male; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000494:pharmacology; D051381:Rats; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D003035:Cobalt; D011092:Polyethylene Glycols; D016572:Cyclosporine; D051547:Heme Oxygenase-1; C018021:cobaltous chloride